Clinical Efficacy and Tolerance of 1% Nadifloxacin Cream in the Treatment of Mild to Moderate Acne Vulgaris in South Korea.
- Author:
Won Jun CHOI
1
;
Kwang Joong KIM
;
Nack In KIM
;
Young Chul KYE
;
Dae Hun SUH
;
Joo Heung LEE
;
Myeung Nam KIM
;
Eun So LEE
;
Ju Hee LEE
;
Young Suck RO
Author Information
1. Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea. romio@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
1% nadifloxacin cream;
Acne;
Treatment
- MeSH:
Acne Vulgaris;
Fluoroquinolones;
Humans;
Korea;
Quinolizines;
Republic of Korea;
Skin
- From:Korean Journal of Dermatology
2010;48(8):665-671
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Antimicrobials have been a mainstay of inflammatory acne treatment for more than 30 years. However, antibiotic-resistant propionibacteria had been isolated with increased frequency, and associated with failure to respond to antibiotic therapy. OBJECTIVE: The aim of this study was to investigate the clinical efficacy and tolerance of 1% nadifloxacin cream. METHODS: In the final analysis, 197 patients with mild to moderate facial acne vulgaris were enrolled. The patients were instructed to apply 1% nadifloxacin cream twice daily to the affected skin after washing the face. Following 2 and 4 weeks of treatment, patients were observed for clinical response: number of the acne lesions, Korea acne grading system (KAGS), global improvement, and occurrence of adverse reactions. RESULTS: During 4 weeks of treatment, nadifloxacin caused significant reduction in the number of inflamed papulo-pustular lesions and open/closed comedones. In addition, significant reduction of KAGS was observed. About 96% of patients showed clinical improvement in the overall evaluation of the therapeutic effect by physicians. All reported adverse events were mild. CONCLUSION: This study shows that 1% nadifloxacin cream can be an effective and safe treatment for mild to moderate acne vulgaris.
